Biotalys Gains California Approval for EVOCA Biofungicide, Clearing Path for EVOCA NG Launch
Event summary
- Biotalys' EVOCA biofungicide received state registration in California on September 2, 2026, meeting stringent regulatory requirements for safety and efficacy.
- The approval follows prior EPA approval in December 2025 and Florida state registration earlier in 2026.
- EVOCA NG, the next-generation version of EVOCA, is expected to launch in the U.S. in 2029, targeting a $1.1 billion market.
- California's approval strengthens Biotalys' regulatory pathway for EVOCA NG, its lead commercial asset.
The big picture
Biotalys' California approval for EVOCA underscores the viability of its protein-based biocontrol platform in one of the world's most demanding regulatory environments. The decision strengthens the company's pathway to commercialize EVOCA NG, positioning it as a potential disruptor in the sustainable crop protection market. California's approval, combined with prior EPA and Florida registrations, provides a strong foundation for Biotalys' U.S. expansion strategy.
What we're watching
- Regulatory Momentum
- Whether Biotalys can sustain this approval pace for EVOCA NG and other pipeline assets.
- Market Penetration
- The pace at which Biotalys can capture share in the $1.1 billion U.S. biofungicide market.
- Commercial Execution
- How Biotalys will position EVOCA NG against chemical alternatives in high-value crop markets.
Related topics